Hong Kong stocks hit by geopolitics as China’s biotech companies in US lawmakers’ cross hairs
- US lawmakers advanced a bill that aims to prohibit federal contracting with certain biotechnology providers connected to ‘foreign adversaries’
- JD.com gained after unveiling share buy-back programmes
The Hang Seng Index closed 1.3 per cent lower at 16,190.34 on Thursday, after gaining as much as 0.5 per cent. The Tech Index lost 1.6 per cent and the Shanghai Composite Index edged down 0.4 per cent.
Thursday’s setback brings the loss this week to 2.2 per cent, following the 6.6 per cent jump last month, as investors fretted about the lack of strong fiscal stimulus package during the “two sessions”, China’s annual parliamentary meeting, and remain concerned about the growth trajectory of the world’s second largest economy.
“Market intervention is never a good sign. It creates a false bottom for Chinese equities,” said Seng Liew, director at Emerging Markets Investors Alliance.
Other Asian markets were mixed. Japan’s Nikkei 225 lost 1.2 per cent after the yen strengthened to the highest level in a month against US dollar. Australia’s S&P/ASX 200 and South Korea’s Kospi Index both gained about 0.2 per cent after Federal Reserve chair Powell said the US central bank will begin dialling back policy restraints at some point this year.